NP/PA Connect
News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
More
Publication
Dermatology Times
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • NP/PA Connect
  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Non-Melanoma Skin Cancers
  • Vitiligo
  • Wound Care
Advertisement

Jean Tang, MD, PhD

Advertisement

Jean Tang, MD, PhD, is a professor of dermatology at Stanford University.

Articles by Jean Tang, MD, PhD

Jean Tang, MD, PhD, Reflects on FDA Approval of pz-cel for EB

ByJean Tang, MD, PhD,Dermatology Times Staff
August 19th 2025
Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Dermatology Times

    1

    Modern, Multi-Modal Approaches to Repigmentation in Patients with Vitiligo

    2

    Amlitelimab Demonstrates Efficacy With Every-12-Weeks Dosing in AD Trials

    3

    Phase 2 Trial Suggests Disease-Modifying Role for Bitopertin in EPP

    4

    Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata

    5

    Galderma Presents Phase 3 Relfydess Data and Dysport Innovations at TOXINS 2026

    • About
    • Advertise
    • Contact Us
    • Job Board
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy Policy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us